logo

Anavex Life Sciences Corp. (AVXL)



Trade AVXL now with
  Date
  Headline
7/6/2020 7:11:16 AM Anavex Says First Participant Enrolled In Phase 1 Study Of ANAVEX3-71
7/1/2020 7:12:52 AM Anavex Says First Patient Dosed In EXCELLENCE Phase 2/3 ANAVEX2-73-RS-003 Clinical Trial
6/16/2020 7:18:30 AM Anavex Exceeds Enrollment Target For ANAVEX 2-73 U.S. Phase 2 Rett Syndrome Clinical Trial
6/4/2020 7:19:12 AM Anavex Life Sciences Gets Approval From Health Canada & UK MHRA Expanding Phase 2b/3 ANAVEX2-73 Into Multinational Trial
5/21/2020 7:15:25 AM Anavex Life Sciences Initiates First-in-Human Phase 1 Study Of ANAVEX®3-71
2/3/2020 7:10:27 AM Anavex Life Sciences: FDA Grants Fast Track Designation For ANAVEX®2-73 Clinical Development Program For Rett Syndrome
10/9/2019 7:07:25 AM Anavex Life Sciences Begins ATTENTION-AD ANAVEX®2-73 Extension Clinical Study In Early Alzheimer’s Disease
9/4/2019 7:07:17 AM Anavex Life Sciences Begins EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study In Pediatric Patients With Rett Syndrome
7/29/2019 7:14:01 AM Anavex Life Sciences Receives Positive Opinion For Orphan Designation From EMA For ANAVEX®2-73 For Rett Syndrome
6/25/2019 7:20:19 AM Anavex Life Sciences Says First Patient Dosed In Extension Study To Its U.S. Phase 2 Clinical Trial Of ANAVEX2-73
6/6/2019 7:18:10 AM Anavex Life Sciences Announces First Patient Dosed In Phase 2 Clinical Trial Of ANAVEX2-73
3/18/2019 7:09:48 AM Anavex Life Sciences Announces First Patient Dosed In Phase 2 Clinical Trial Of ANAVEX®2-73 For Rett Syndrome In U.S.
2/7/2019 7:24:42 AM Anavex Life Sciences Q1 Net Loss $7.33 Mln Or $0.16/Shr Vs Loss $4.06 Mln Or $0.09/Shr Last Year
1/2/2019 7:03:19 AM Anavex Life Sciences Appoints Walter Kaufmann To Chief Medical Officer